VahatiCor develops the A-FLUX Reducer System for coronary microvascular dysfunction relief.
VahatiCor has raised $23.0M in total funding. The most recent round was Series B. The last funding was announced in November 2025.
VahatiCor's investors include S3 Ventures, Intuitive Ventures.
VahatiCor is headquartered in Santa Clara, United States.
VahatiCor develops the A-FLUX Reducer System for coronary microvascular dysfunction relief.
VahatiCor is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VahatiCor — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/vahaticor. Accessed July 31, 2026.
VCBacked. (2025). VahatiCor — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/vahaticor
{{cite web |title=VahatiCor — Funding & Investors |url=https://www.vcbacked.co/company/vahaticor |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated